natgillin/translations-raw huggingface dataset:
The BCA system according to claim 1, wherein said processed parasitized mealybug mummies are encased in specially adapted packaging for storing, delivering and/or distributing said modified parasitized mealybug mummies. 
Sustav BCA iz zahtjeva 1, naznačen time da su navedene obrađene mumije parazitiranih vunastih ušiju zatvorene u pakiranje posebno prilagođeno za skladištenje, isporuku i/ili distribuciju navedenih modificiranih mumija parazitiranih vunastih ušiju.
The method of claim 8, wherein the conduit further comprises a shut down valve and/or a quick release system. 
Postupak prema zahtjevu 8, naznačen time da vod (52) dodatno sadrži ventil za isključivanje (410) i/ili sustav za brzo otpuštanje (340).
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-13, wherein the treatment comprises administration of the anti-PD-1 antibody after administration of the anti-LAG-3 antibody. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-10, gdje liječenje obuhvaća administraciju anti-PD-1 antitijela nakon administracije anti-LAG-3 antitijela.
An advantage of this variation is that it does not involve the formation of Mosher's acid esters and therefore avoids the chromatographic separation typically used to separate Mosher's acid esters. 
Prednost ove varijacije je da ne obuhvaća formiranje estera Mosher-ove kiseline i tako izbjegava kromatografsko odijeljivanje koje se obično koristi za odijeljivanje estera Mosher-ove kiseline.
There is a preference for isoquinoline derivatives of Formula I wherein Y is OH. 
Izokinolinski derivat u skladu s patentnim zahtjevom 1 ili 2, gdje Y je OH.
preparing an aqueous solution comprising about 3-10% whey protein, a pH value of about 7 to 9, wherein the calcium concentration of the whey protein is 1.4 mM or less or has been reduced at least about 50%; 
(vi) pripremu vodene otopine koja sadrži 3 do 10% proteina sirutke, ima pH vrijednost od 7 do 9, a koncentracija kalcija u proteinu sirutke iznosi 1.4 mM ili manje ili je smanjena za barem 50%, poželjnije za barem 98%;
This requires that focus be put on the tolerances allowed when metal and plastic has to cooperate. 
Ovi zahtjevi se usredotočuju na tolerancije koje se dopuštaju kada se zajedno koriste metal i plastika.
The compound according to claim 1, wherein said compound has formula (VI): wherein 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VI):
This material was carried on to the next step without any further purification. 
Taj se materijal prenosi u slijedeći korak bez daljnjeg pročišćavanja.
A pharmaceutical composition comprising an effective amount of the compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema patentnom zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli 1 farmaceutski prihvatljiv nosač.
The steel according to claim 9, wherein the microstructure is free from M6X. The steel according to claim 1, wherein the Equivalent Circle Diameter (ECD) of the carbides and carbonitrides in a microstructure is less than 1.5 um. 
Čelik proizveden metalurgijom praha za hladnu obradu čelika prema bilo kojem od patentnih zahtjeva 7 -9, naznačen time što je ekvivalentni promjer kruga (ECD) karbida i karbonitrida u mikrostrukturi manji od 1,5 µm, poželjno manji od 1,0 µm.
The liquefied gas treatment system according to claim 3, wherein the sub LNG supply line (L24) includes a gas-liquid separator (46) configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje separator plina od tekućine (23), konfiguriran za razdvajanje BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), na plinovitu komponentu i tekuću komponentu.
A combination of Claim 6 wherein in the compound of formula Ia R3, R4 and the carbon atom to which they are attached together form -C3-6cycloalkyl. 
Spoj prema patentnom zahtjevu 6 naznačen time što Rs, Rx i atom ugljika za koji su vezani zajedno formiraju -Ca.sCikloalkil.
where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those used in the previous example; 
(xii)kada se za sintezu kaže da je analogna sintezi opisanoj u prethodnom primjeru, tada su količine korištene u toj sintezi ekvivalenti milimolarnog udjela korišteni u prethodnom primjeru;
The process of claim 9 wherein the iodic acid is added when the reaction mixture has a pH comprised from 5 to 6. 
Postupak prema zahtjevu 9 naznačen time da se jodna kiselina dodaje kada reakcijska smjesa ima pH u rasponu od 5 do 6.
In a preferred embodiment, the invention provides an antibody or antigen-binding fragment thereof, which binds human IL-6 receptor (SEQ ID NO:1) with a KD of about 500 pM or less, as measured by surface plasmon resonance. 
PATENTNI ZAHTJEVI Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na receptor humanoginterleukina 6 (hIL-6R) sa konstantom Kp od 500 pM ili manje, izmjereno površinskom plazmon rezonancijom, naznačen time, da:
Stirred at ambient temperature for 18h, the reaction mixture was then poured into water (100 mL). 
Kroz 18 sati se miješa na sobnoj temperaturi, reakcijska smjesa se prelije u vodu (100 ml).
time interleaving the preamble data symbols excluding pilot positions in the preamble data symbols; frequency-interleaving the time-interleaved preamble data symbols; 
umetanje vremena simbolima podataka početnog niza osim pozicija pilota u simbolima podataka početnog niza;
applied on the underside of the core, there are a base coat layer and a layer of counterbalancing material, 
na donju stranu jezgre je primijenjen temeljni sloj i sloj protutežnog materijala,
The method of Claim 13, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein R10 and R11 are each, independently, -F, -Cl, a C1-C4 alkyl, a C1-C4 haloalkyl, a C1-C4 alkoxy and a C1-C4 haloalkoxy. 
[image] (XIII) ili njegova farmaceutski prihvatljiva sol, solvat ili klatrat pri čemu: i R11 su svaki, nezavisno, -F, -Cl, C1-C4 alkil, C1-C4 haloalkil, C1-C4 alkoksi i C1-C4 haloalkoksi.
The composition according to claim 21, wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
intravenoznog, intraarikularnog, intrabronhijalnog, intraabdominalnog, = intrakapsularnog, = intrahrskavičnog, intrakavitarnog, = intracelijalnog, = intracerebelarnog, intracerebroventrikularnog, davanja putem debelog crijeva, intracervikalnog, intragastričnog, intrahepatičnog, intramiokardijalnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatskog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasmovijalnog, intratorakalnog, intrauterinog, intravezikularnog, imtralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, podjezičnog, intranazalnog, 1 transdermalnog načina davanja; ili
The matches 9 can be made of either one cardboard sheet 30 featuring incisions 32, by means of which safety matches are united into one entirety, or both cardboard sheets 30 with incisions 32 can be glued together and to the box, while the match heads 31 are situated reversely, on opposite sides. 
Å ibice 9 mogu biti napravljene bilo od jedne kartonske pločice 30 sa zasjecima 32, gdje su šibice spojene u jednu cjelinu, ili obje kartonske pločice 30 sa zasjecima 32 mogu biti zalijepljene međusobno i na kutiju, dok su glave šibica 31 okrenute jedne nasuprot drugima. HR P20080341 T3 PATENTNI ZAHTJEVI
0.01% The formulation was prepared by using a suitable stainless steel dissolution tank, provided with a stirrer and a heating-cooling jacket. 
0,01% Formulacija je pripremljena koristeći odgovarajuću zatvorenu posudu za otapanje od nehrđajućeg čelika, s mješalicom i omotom za grijanje-hlađenje.
A polymorphic form of Compound (1) according to claim 1, represented by the following structural formula for use in treating influenza infection wherein said polymorphic form is administered to a subject in a dosage amount of 100 mg to 1,600 mg, and wherein the dosage amount is administered once, twice or three times per day. 
N >NH Q HN * oH naznačen time što je namijenjen upotrebi u liječenju infekcije influencom, gdje se navedeni polimorfni oblik primjenjuje na subjektu u količini doze od 100 mg do 1600 mg, te gdje se količinu doze primjenjuje jednom, dva puta ili tri puta dnevno.
A genetically modified mouse that expresses human immunoglobulin heavy and light chain variable domains, wherein the human light chain variable domains are expressed from a single rearranged (VL/JL) human immunoglobulin light chain variable region gene sequence present in the mouse germline that comprises a germline sequence of a VL gene segment and a germline sequence of a JL gene segment, said human immunoglobulin light chain variable region being a rearranged Vk1-39/Jk, wherein: 
zamjenu genskih segmenata varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina na lokusu varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina s jednostrukim preuređenim humanim genskim segmentom Vk1-39/Jk ili jednostrukim preuređenim humanim genskim segmentom Vk3-20/Jk, pri čemu je humani genski segment operativno povezan na endogeni mišji konstantni gen k i pri čemu mišu nedostaje lokus lakog lanca endogenog mišjeg k imunoglobulina koji je sposoban preurediti i formirati gen koji kodira mišju k varijabilnu regiju i
In US 4,477,534 the resin contain unsaturated fatty acid esters and the reactive diluent an air drying vinyl oxazoline ester. 
U US 4,477, 534 smola sadrži estere nezasićenih masnih kiselina i zrakom sušeni vinil oksazolin ester kao reaktivno sredstvo za razrjeđivanje.
the balance being Fe and unavoidable impurities; as a construction material for a component for a urea manufacturing plant, wherein the component is in contact with a fluid selected from the group consisting of carbamate solutions and ammonia and carbon dioxide containing gases, particularly as present in the synthesis section of said plant under condensing conditions, and wherein the component comprises one or more surfaces resulting from the object having been processed by a technique selected from the group consisting of machining, drilling, and combinations thereof. 
0- 0,03; Ce 0-02 ostatak čini željezo i neizbježne primjese; kao građevni materijal za komponentu za pogon za proizvodnju uree, pri čemu je navedena komponenta u kontaktu s tekućinom odabranom iz grupe koja uključuje karbamatne otopine, amonijak i ugljikov dioksid s plinovima, poglavito one prisutne prilikom kondenzacije u sekciji sinteze uree, pri čemu navedena komponenta obuhvaća jednu ili više površina dobivenih strojnom obradom predmeta ili bušenjem ili kombinacijom ove dvije tehnike.
The compound for use according to claim 8, wherein at least one internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage and at least one internucleoside linkage of the modified oligonucleotide is a phosphodiester internucleoside linkage. 
Spoj za upotrebu prema zahtjevu 7, pri čemu bar jedna internukleozidna veza modificiranog oligonukleotida je fosforotioatna internukleozidna veza i bar jedna internukleozidna veza modificiranog oligonukleotida je fosfodiestarska internukleozidna veza.
The method according to claim 1, wherein the second waste mineral wool is mixed with fly ash before it is supplied directly to the inlet conduit. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu se drugi dio otpadne mineralne vune miješa s pepelom prije prije dovoda kroz ulaznu cijev (4).
Therefore, in one embodiment the present invention provides an detectably labeled antibody, wherein the detectable label is selected from the group consisting of an enzyme, a radioisotope, a fluorophore and a heavy metal 
Antitijelo u skladu s patentnim zahtjevom 9, naznačeno time, da je detektabilna oznaka odabrana iz skupine koju čine enzim, radioizotop, fluorofor i teški metal.
Process according to claim 8 comprising the additional subsequent step of recycling at least part of the treated waste water downstream said tertiary treatment unit as technical water. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što uključuje dodatni naknadni korak recikliranja u najmanju ruku dijela obrađene otpadne vode nizvodno od navedene jedinice za tercijarnu obradu kao tehničke vode.
The method according to claim 2, wherein the compound is coupled to KLH (Keyhole Limpet Hemocyanin). 
Peptid prema zahtjevu 8, naznačen time, da se peptid spaja na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
The formulation according to claim 1, wherein the fumaric acid ester is a mono-(C1-C5) alkylester of fumaric acid that is present in the form of a pharmaceutically acceptable salt. 
Formulacija prema bilo kojem prethodnom zahtjevu, naznačena time, da ester fumarne kiseline je mono-(Ci-Cs) alkilester fumarne kiseline koji je prisutan u obliku farmaceutski prihvatljive soli.
An ophthalmic pharmaceutical composition comprising 0.05 mg/ml to about 7 mg/ml of a compound of Formula I as defined in claim 1, and a pharmaceutically acceptable carrier consisting of, from 1 mg/ml to about 140 mg/ml of hydroxypropyl B-cyclodextrin in saline for injection. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 9, koji je topička oftalmička formulacija za snižavanje intraokularnog tlaka obuhvaća od 0.05 mg/mL do otprilike 7 mg/mL tvari kako je definirana u patentnom zahtjevu 1, 10d 1 mg/mL do otprilike 140 mg/mL hidroksipropil B-ciklodekstrina u fiziološkoj otopini za injekcije.
The process of claim 18, wherein the basic lithium alkylamide is lithium diisopropylamide. The process of claim 18, wherein the electrophile is selected from the group defined in the following table, to generate the corresponding R23 in the table: 
Postupak sukladno bilo kojem od patentnih zahtjeva 11-13, naznačeno time, da se navedeni elektrofil izabire iz skupine utvrđene slijedećom tabelom, da bi se generirao odgovarajući raspored R23 prikazan u navedenoj tabeli:
A system according to claim 1, wherein the transceiver of each of the two or more short-range phone interface units is a Bluetooth chip. 
Sustav sukladno zahtjevu 1, naznačen time da primopredajnik svakog od dvaju ili više sučelja telefona kratkog dometa sadrži "Bluetooth" čip.
A method according to embodiment 45, wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder. A method according to embodiment 45, wherein said autoimmune disease is rheumatoid arthritis. 
Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da a) navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili b) navedena autoimuna bolest predstavlja reumatoidni artritis; ili
releasing the hydrostatic pressure; with the proviso that the said viable biological material is not human. 
(c) otpuštanje hidrostatskog tlaka; uz uvjet da navedeni vijabilni biološki materijal nije ljudski.
Removable hydroxyl blocking groups include conventional substituents such as allyl, benzyl, acetyl, chloroacetyl, thiobenzyl, benzylidene, phenacyl, t-butyldimethylsilyl and trialkylsilyls such as triethylsilyl, triisopropylsilyl, trimethylsily, tributylsilyl and the like, and any other group that can be introduced chemically onto a hydroxyl functionality and later selectively removed either by chemical or enzymatic methods in mild conditions compatible with the nature of the product. 
Blokirajuće grupe za hidroksilnu grupu, a koje se kasnije mogu ukloniti, uključuju uobičajene supstituente kao što su alil, benzil, acetil, kloroacetil, tiobenzil, benziliden, fenacil, t-butildimetilsilil i trialkilsilile kao što su trietilsilil, triizopropilsilil, trimetilsilil, tributilsilil i slično, kao i bilo koju drugu grupu koja se može kemijski uvesti na hidroksilnu funkciju, a kasnije selektivno ukloniti bilo kemijskim ili enzimskim procesom u blagim uvjetima, koji odgovaraju prirodi produkta.
a level arm (45) in the form of a rod, which is fixed at one end thereof, comprises an opening in the middle thereof in which the pin (44) may move back and forth, and moves circularly around the axis of its fixed end with the movement of the pin (44), 
- - polugu (45) u obliku šipke, koja je fiksirana na jednom svom kraju, ima otvor u sredini u kojem se klin (44) može pomicati naprijed-natrag, i miče se kružno oko osi svog fiksiranog kraja s pomicanjem klina (44),
A composition comprising the isolated IL-23p19 antibody fragment according to claim 1 or 5 and at least one pharmaceutically acceptable carrier or diluent. 
kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;(b) sadrži najmanje jednu od:
The method of clause 30 further comprising: fastening first trusses to the first and second wall panels so that the first trusses support a ceiling of a first space defined at least partially by the first and second wall panels and a floor of a second space defined at least partially by the third and fourth wall panels; and, 
Postupak prema zahtjevu 4, naznačen time da nadalje sadrži: pričvršćivanje prvog rešetkastog nosača poda i/ili stropa na integrirani rešetkasti dio prve konstrukcijske rešetkaste ploče tako da prva rešetka poda i/ili stropa nosi element koji sadrži strop prvog prostora definiranog barem djelomično s prvom strukturnom rešetkastom pločom (20) i pod od drugog prostora definiranog barem djelomično s drugom strukturnom rešetkastom pločom (20); te
An in vitro method of inducing a cytotoxic T cell, comprising the steps of: contacting an antigen-presenting cell with a peptide of any one of claims 1 to 9, and 
Postupak induciranja citotoksične T-stanice in vitro, naznačen time što se sastoji u koracima: (i) stavljanja u kontakt stanice za predočavanje antigena s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i
CNS 7056 or the salt or solvate for use according to any of the above claims, wherein the besylate salt of CNS 7056 is used. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od zahtjeva 1 do 5 i 8, naznačen time što maksimalna doza fentanila po tretmanu ne prelazi 200 mcg/pacijentu.
A method for treating or preventing a cardiovascular disease, comprising administering an effective amount of the peptide or pharmaceutically acceptable salt of the peptide of any one of embodiments 1 to 75 to a mammal in need thereof. 
Peptid ili farmaceutski prihvatljiva sol navedenog peptida prema bilo kojem od zahtjeva 1 do 13, ili pripravak prema zahtjevu 14, naznačen time da je za uporabu za liječenje ili spriječavanje dislipidemije, kardiovaskularne bolesti, endotelijalne disfunkcije, makrovaskularnog poremećaja i/ili mikrovaskularnog poremećaja kod sisavca.
The size of the take off board can be lengthened in order to help the flying of the bees. 
Veličina ploče koja se skida (82) može se produljiti za pomoć pčelama pri uzlijetanju.
The method of item 3, wherein the hydrogen donor is methanol, ethanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, cyclopentanol, cyclohexanol, benzylalcohol, a menthol, formic acid, lactic acid, ascorbic acid, mandelic acid, ammonium formate, potassium formate, cyclohexadiene, cyclohexene, 1-methylcyclohexene, tetralin, dihydrofuran, a terpene, diazene, hydrazine, hydroxylamine, or NaH2PO2, or a mixture thereof. The method of item 3, wherein the hydrogen donor is formic acid, ammonium formate, potassium formate, cyclohexene, 1-methylcyclohexene, NaH2PO2, or a mixture thereof The method of item 3, wherein the hydrogen donor is a C1-14 carboxylic acid. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je donor vodika metanol, etanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, ciklopentanol, cikloheksanol, benzilalkohol, mentol, mravlja kiselina, mliječna kiselina, askorbinska kiselina, bademova Kiselina, amonijev formijat, kalijev formijat, cikloheksadien, cikloheksen, 1-metilcikloheksen, tetralin, dihidrofuran, terpen, diazen, hidrazin, hidroksilamin ili NaH2PO2, ili njihova smjesa; ili gdje je donor vodika mravlja kiselina, amonijev formijat, kalijev formijat, cikloheksen, 1-metilcikloheksen, NaH2P02, ili njihova smjesa; ili gdje je donor vodika C1-14 karboksilna kiselina.
and R5, taken together with the carbon atom to which they are attached to, may form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or any one of R4 and R5 in X and any one of R4 and R5 in Y combined together, when they are attached to carbon atoms, may form a 4- to 7- membered substituted or unsubstituted heterocyclic ring in order to give a bicyclic heterocyclic ring; ring D is selected from 
R4 i Rs, uzeti zajedno sa atomom ugljika za koji su vezani, mogu formirati supstituirani ili nesupstituirani 3- do 7-člani karbociklični ili heterociklični prsten; ili bilo koji od Rx, i Rs u X i bilo koji od R4 i Rs u Y kombinirani zajedno, kada su vezani za atome ugljika, mogu da formiraju 4- do 7- člam supstituirani ili nesupstituirani heterociklični prsten u cilju dobijanja bicikličnog heterocikličnog prstena; prsten D je izabran od
A solution of 70 mg/L polyalanine in methanol was used as the lockmass (the internal calibrant). 
Otopina 70 mg/L polialanina u metanolu se upotrijebi kao standard (unutarnje sredstvo za kalibriranje).
A pharmaceutical composition comprising an effective amount of the rifaximin t together with pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži djelotvornu količinu kristalnog oblika T rifaksimina u skladu s patentnim zahtjevom 1, uz farmaceutski prihvatljive pomoćne tvari.
a polypeptide comprising residues 4-725 of SEQ ID NO:4; or a polypeptide consisting of residues 1 and 4-725 of SEQ ID NO:4 optionally with a His tag inserted following the initial Met residue; or 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 14-725 iz SEQ ID NO<4, izborno s ubačenim biljegom His iza početnog ostatka Met.
a second ring member (201) having second indicia, the second ring member being rotatable in increments about the same axis as the first ring member, the second indicia indicating a count; 
drugi prstenasti element (201) koji ima drugu indikaciju, pri čemu se drugi prstenasti element može rotirati postepeno oko iste osi kao prvi prstenasti element, pri čemu druga indikacija indicira brojanje;